The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2
Author:
Funder
Cancer Council NSW
Publisher
Elsevier BV
Subject
Pharmacology,Biochemistry
Reference44 articles.
1. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells;Druker;Nat Med,1996
2. Clinical pharmacology of axitinib;Chen;Clin Pharmacokinet,2013
3. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib;Haouala;Blood,2011
4. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine;Infante;Cancer Chemother Pharmacol,2012
5. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours;Awada;Eur J Cancer,2012
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants;European Journal of Pharmaceutical Sciences;2024-08
2. The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms;Frontiers in Immunology;2023-05-31
3. Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2;Current Drug Metabolism;2021-03-22
4. Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS;Chemico-Biological Interactions;2019-09
5. Interaction between phytotherapy and oral anticancer agents: prospective study and literature review;Medical Oncology;2019-04-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3